Shanghai Yizhong Pharmaceutical Co (SHSE:688091) Research & Development: ¥104.5 Mil (TTM As of Mar. 2026)


SHSE:688091 Shanghai Yizhong Pharmaceutical Co Ltd SHSE:688091
60 GF Score
Price ¥40.20
GF Value ¥49.38
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Shanghai Yizhong Pharmaceutical Co Research & Development?

Shanghai Yizhong Pharmaceutical Co SHSE:688091 -1.59% 60 Research & Development is ¥104.5 Mil as of Mar. 2026. GuruFocus rates SHSE:688091 with a GF Score™ of 60/100 and a GF Value™ of ¥49.38 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shanghai Yizhong Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was ¥27.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥104.5 Mil.

Shanghai Yizhong Pharmaceutical Co  (SHSE:688091) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shanghai Yizhong Pharmaceutical Co Research & Development Related Terms

Shanghai Yizhong Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Shanghai Yizhong Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Yizhong Pharmaceutical Co Research & Development Chart

Shanghai Yizhong Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 13.24 7.93 22.45 37.20 86.37

Shanghai Yizhong Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.28 19.49 25.74 31.86 27.36
SHSE:688091
60GF Score
Shanghai Yizhong Pharmaceutical Co Ltd SHSE:688091
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Yizhong Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥104.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥104.5 Mil mean?
Shanghai Yizhong Pharmaceutical Co (SHSE:688091) has a Research & Development of ¥104.5 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Yizhong Pharmaceutical Co and its competitors.
Is Shanghai Yizhong Pharmaceutical Co's Research & Development too high?
Shanghai Yizhong Pharmaceutical Co's current Research & Development is ¥104.5 Mil. Overall, Shanghai Yizhong Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Yizhong Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Shanghai Yizhong Pharmaceutical Co's Research & Development of ¥104.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Yizhong Pharmaceutical Co and its competitors. Shanghai Yizhong Pharmaceutical Co's current Research & Development is ¥104.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Yizhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co (SHSE:688091) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥49.38, compared to a current price of ¥40.20 — trading 18.6% below its estimated fair value. The current Research & Development is ¥104.5 Mil. Shanghai Yizhong Pharmaceutical Co's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shanghai Yizhong Pharmaceutical Co (SHSE:688091), the current Research & Development is ¥104.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Yizhong Pharmaceutical Co (SHSE:688091) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥40.20 is trading 18.6% below its estimated GF Value™ of ¥49.38. GuruFocus considers Shanghai Yizhong Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:688091:

  • Research & Development: ¥104.5 Mil
  • GF Value™: ¥49.38 vs. price of ¥40.20 (18.6% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688091 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Yizhong Pharmaceutical Co Business Description

Address 79 Renqi Road, Fengxian District, Shanghai, CHN, 201403
Shanghai Yizhong Pharmaceutical Co Ltd is a pharmaceutical enterprise integrating research and development, production and sales. It is committed towards the development of new dosage forms of anti-tumor drugs and related products.
60GF Score

Get the complete analysis for SHSE:688091

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥40.20
Price
¥49.38
GF Value